Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph’s Healthcare Hamilton, together with colleagues at other partnering institutions, have developed a new method to treat severe asthma.
In a study of over 200 participants with severe asthma, the new treatment was shown to have improved asthma symptoms and lung function, while reducing the need for corticosteroids by up to 70%.
According to Statistics Canada, eight per cent of Canadians aged 12 or older – approximately 2.4 million people – have been diagnosed with asthma. Of that, approximately 25% are considered to be severe cases of asthma.
Current treatments for severe asthma often include high doses of corticosteroids, such as prednisone, to control exacerbations. Reducing the need for corticosteroids with alternative treatments is preferable, since these medications are associated with serious side effects from prolonged use – including multi-organ toxicities and immunosuppression.
Parameswaran Nair, professor of medicine at McMaster and staff respirologist at St. Joseph’s Healthcare Hamilton, along with a team of researchers found that an antibody called dupilumab is effective in treating severe asthma in place of high doses of prednisone.
The results were published in the New England Journal of Medicine, one of the world’s most influential medical publications.
Researchers sought participants who had been using oral corticosteroids (prednisone) to treat severe asthma for at least six months prior to the study. In addition to their standard regimen of corticosteroids, patients received either dupilumab or a placebo during the 24 week trial. The corticosteroid dose was gradually reduced during weeks four to 20, and maintained at a low level for the final four weeks.
“The ability of dupilumab to increase lung function as markedly as it did in this study, even in the face of [corticosteroid] withdrawal, indicates that it appears to be inhibiting key drivers of lung inflammation,” the researchers noted.
Dupilumab works to treat asthma by blocking two specific proteins (called interleukin-4 and interleukin-13) that are associated with inflammation of the airways.
This technique was based on Nair’s previous research, (published in the New England Journal of Medicine in 2009 and in 2017). Those studies found that blocking another protein, interleukin-5, allowed patients with high eosinophil levels in their blood and airways to reduce their corticosteroid dose. Eosinophils are a type of white blood cell involved with the production of interleukins. High eosinophil levels are directly linked to an increased risk of severe asthma.
Unlike the previous studies, dupilumab was shown to be effective regardless of patients’ eosinophil levels. Despite the reduced prednisone dose, patients in this study not only experienced a decrease in asthma exacerbations, but their lung function also improved significantly.
“Ultimately, our goal is to find new treatment pathways that allow us to circumvent the use of corticosteroids,” said Nair.
“Since dupilumab showed a significant improvement on asthma control regardless of eosinophil levels, we may be able to use this treatment for a wider range of patients than we previously thought possible. This might be due to the broad effects on inflammation in asthma of the two proteins that we were able to block with dupilumab. The treatment was not associated with any serious side effects.”
The Latest on: Asthma
via Google News
The Latest on: Asthma
- Asthma Therapeutics Market Size and Key Trends in Terms of Volume and Value 2017 – 2025 on November 12, 2018 at 11:39 am
Albany, NY -- (SBWIRE) -- 11/12/2018 -- Asthma is a chronic disease of airways of the lungs and characterized by various symptoms such as bronchospasm, and pulmonary airway obstructions. The symptoms ... […]
- Asthma Cases Spike in Puerto Rico Following 2017 Hurricane Season on November 12, 2018 at 11:05 am
Mold is a very well documented asthma trigger for many who suffer from the condition and exposure to exhaust from generators doesn’t help anyone with a respiratory condition. Earlier this year, NBC Ne... […]
- FDA approves return of popular Primatene Mist asthma inhaler on November 12, 2018 at 11:04 am
TRENTON, N.J. (AP) — A new version of the once-popular asthma inhaler Primatene Mist will soon return to U.S. stores. The Food and Drug Administration approved the over-the-counter aerosol inhaler lat... […]
- Several Asthma, Allergy Groups Express "Deep Concern" Over Primatene MIST Approval on November 12, 2018 at 10:07 am
In a joint statement, the Allergy & Asthma Network, the American Association for Respiratory Care, the American College of Allergy, Asthma & Immunology (ACAAI), the American College of Chest Physician... […]
- EXCLUSIVE: Family Allergy & Asthma acquires largest Louisville competitor, two other offices on November 12, 2018 at 9:38 am
Louisville-based Family Allergy & Asthma announced Monday that it has acquired its largest competitor in the Louisville market, Kentuckiana Allergy PSC, as well as two smaller practices. Terms of the ... […]
- When I Experienced Medical Gaslighting During an Asthma Attack on November 11, 2018 at 10:21 pm
Having a chronic illness can be tough. You can’t even begin to explain to anyone what it’s like to have something looming over your head all the time — like a cloud hanging out over your head or like ... […]
- Medicaid Coverage of Guidelines-Based Asthma Care Across 50 States, the District of Columbia, and Puerto Rico, 2016-2017 on November 11, 2018 at 10:10 pm
Quick relief medications Fast acting or quick relief medications intended to provide immediate relief of bronchoconstriction and its accompanying acute symptoms. Controller medications Long-term contr... […]
- FDA Decision to Approve Primatene Mist Endangers Asthma Patients, According to Allergy & Asthma Network and Asthma Community Stakeholders on November 9, 2018 at 3:41 pm
VIENNA, Va., Nov. 9, 2018 /PRNewswire/ -- A group of asthma community stakeholders released a joint statement today expressing deep concern over the Food and Drug Administration's (FDA) decision to ap... […]
- The 2018 Asthma Market and Competitive Landscape in Europe - ResearchAndMarkets.com on November 9, 2018 at 9:28 am
DUBLIN--(BUSINESS WIRE)--The "Europe Asthma Market and Competitive Landscape - 2018" report has been added to ResearchAndMarkets.com's offering. This latest research provides comprehensive ... […]
via Bing News